AU1700899A - Gram-positive microorganism formate pathway - Google Patents

Abstract

The present invention relates to the formate transport system in gram-positive microorganisms and provides methods for the production of products in a gram-positive microorganism. The present invention also provides the nucleic acid and amino acid sequences of FTAP 1 and FTAP 2 which are associated with formate transport.

Description

WO 99/27107 PCT/US98/24873 GRAM-POSITIVE MICROORGANISM FORMATE PATHWAY Field of The Invention The present invention relates to the field of molecular biology and in particular to 5 the identification of molecules involved in formate transport and utilization in Bacillus. The present invention also provides methods for increasing the yields of polypeptides produced in Bacillus. Introduction 10 Gram-positive microorganisms, such as Bacillus, have been used for large-scale industrial fermentation due, in part, to their ability to secrete their fermentation products into the culture media. Secreted proteins are exported across a cell membrane and a cell wall, and then are subsequently released into the external media. It is advantageous to produce proteins of interest in gram-positive microorganisms since exported proteins Is usually maintain their native conformation. Suppmann et al. ( 1994, Molecular Microbiology vol. 11(5), pg. 965-982) describe a putative formate transporter in a gram-negative microorganism, E.coli. Nagy et al. (1995, Journal of Bacteriology, vol: 177, pg. 1292) describe a formyltetrahydrofolate hydrolase in E.coli. Mazel et al (1997, J. Mol. Biol. 266:939-949) describe a polypeptide deformylase 20 function in Eubacterial lineage. Little is known, however, about the uptake and utilization of formate in gram-positive microorganisms used in large scale fermentation methods for the production of heterologous proteins. Gene products which may be associated with formate utilization have been identified in Bacillus. An operon for the production of the co-enzyme tetrahydrofolate 25 (THF) was disclosed by de Siazieu (1997, Microbiology 143:979-989). It is also known that a 10-formyltetrahydrofolate synthetase (ligase) activity and a 5,10-methylenetetrahydro folate dehydrogenase have been shown to exist in B. subtilis (Whitehead et al., 1988, Bacteriology 170:995-997) and Saxild et al. ( 1994, Mol. Gen. Genet. 242:415-420) have identified a 5'-phosphoribosyl-1-glycinamide (GAR) transforylase which catalyses a one 30 carbon transfer reaction in purine biosynthesis. This enzyme, the product of the purT locus, was found to be dependent on formate added either to the growth medium or to in vitro assays using cell-free extracts. There remains a need in the art to optimize gram-positive expression systems so that production of products in these systems can be increased. 35 Summary of the Invention Prior to the present invention, very little was known about formate transport, utilization or cycling in gram-positive microorganisms. While studying the effect of different WO 99/27107 PCT/US98/24873 -- 2additives on the growth of a gram-positive microorganism, Bacillus, in shake flask, a growth enhancement phenomenon was observed when sodium formate was added to the medium. Also, in the absence of exogenous formate, the phenomenon of endogenous formic acid production during gram-positive microorganism fermentation was observed. 5 The present invention is therefore based, in part, upon the modification(s) in gram positive microorganism growth observed in the presence of endogenous or exogenous sodium formate. The present invention is also based upon the evidence presented herein that formate is transported into Bacillus by a symport transport mechanism. Accordingly, the present invention provides a method for modifying the growth of gram-positive 10 microorganisms comprising modifying formate transport in the gram-positive microorganism. The present invention is also based, in part, upon the identification and characterization of four Bacillus proteins found encoded by genomic nucleic acid sequences of Bacillus subtilis which appear to be associated with the formate transport, 15 utilization and cycling: formate transport associated protein 1 (FTAP1) and formate transport associated protein 2 (and FTAP2) which have about 35% and 30% identity, respectively, with the E.coli protein FocA, a formate channel protein; Bacillus subtilis PurU, which has about 48% identity at the amino acid level with PurU of E.coli, a N10 formytetrahydrofolate hydrolase which is involved in the cycling of tetrahydrofolate and 20 formyl tetrahydrofolate, and a formylmethionine deformylase (FMID), which has about 40% similarity to a formylmethionine deformylase (YkrB). The present invention is further based upon data which shows that in the presence of exogenous formate, a Bacillus cell cultured in shake flask and having an interruption of the gene encoding FTAP1 exhibits about a 50% decrease in the growth enhancement 25 normally seen in the presence of exogenous formate. In the presence of exogenous formate, a Bacillus cell cultured in shake flask and having an interruption of the gene encoding FTAP 2 grows more slowly and the density of the culture declines over time. Thus, it appears that FTAP 1 and FTAP 2 are associated with formate transport and utilization in Bacillus. 30 Therefore, modulating the expression of molecules involved in formate transport, utilization and cycling, e.g., FTAP 1, FTAP 2, PurU, and FMD either individually or in combination with each other or other associated molecules, provides a means for regulating the levels of formate production in gram-positive microorganisms. It may be desirable to increase the expression of such molecules, decrease the expression of such 35 molecules, or regulate the expression of such molecules, i.e., provide a means for expressing such molecules during a defined time in cell growth, depending upon the type of gram-positive microorganism and culture conditions desired.

WO 99/27107 PCT/US98/24873 -- 3- Accordingly, the present invention provides a method for increasing the production of a product in a gram-positive microorganism comprising the steps of obtaining a microorganism capable of expressing the product and comprising nucleic acid encoding either one or both of i) formate transport associated protein 1 (FTAP 1) and ii) formate S transport associated protein 2 (FTAP 2); and culturing said microorganism in the presence of formate and under conditions suitable for expression of said product. The product includes naturally occurring products obtainable from a gram-positive microorganism, such as anti-microbial compounds, antibiotics, antigens, antibodies, surfactant, chemical products and enzymes, as well as products, such as proteins and polypeptides, which are 10 encoded by recombinantly introduced nucleic acid. In one aspect, the product is a recombinant protein. In one embodiment, the recombinant protein is homologous to said gram-positive microorganism and in another embodiment, the recombinant protein is heterologous to said gram-positive microorganism. In one aspect of the present invention, the gram-positive organism is a Bacillus and in yet 15 another embodiment, the Bacillus includes B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. coagulans, B. circulans, B. lautus and Bacillus thunngiensis. In one aspect of the present invention, the recombinant protein includes hormones, enzymes, growth factor and cytokine and in another, the enzyme includes protease, lipase, 20 amylase, pullulanase, cellulase, glucose isomerase, laccase and a protein disulfide isomerase. Under large scale Bacillus fermentation conditions performed in the absence of exogenous formate, an excess of endogenous formate or formate "spillover" has been observed in the culture media. Therefor, it may be desirable to delete, mutate or otherwise 25 interrupt the genes encoding FTAP 1 and 2 in order to maintain appropriate endogenous formate levels. Accordingly, the present invention provides a method for producing a product in a gram-positive microorganism comprising the steps of obtaining a gram-positive microorganism capable of expressing said product said microorganism having a mutation in the nucleic acid encoding either one or both of FTAP 1 and FTAP 2 said mutation resulting 30 in inhibition of production by said microorganism of the FTAP 1 and/or FTAP 2 activity; and b) culturing said microorganism under conditions suitable for expression of said product. Furthermore, based upon the overall amino acid sequence homology of Bacillus PurU with E.coli PurU, it appears that Bacillus PurU plays a role in formate transport by acting as an N 10 -formyltetrahydrofolate hydrolase. Saxild et al (1994, Mol. Gen. Genet. 35 242:415-420) speculate that B. subtilis can produce formate via the deformilation of N10 formyl-THFA and of N-formyl-methionine. Accordingly, under growth conditions where excess endogenous formate appears to be spilling outside the normal formate transport pathway, it may be desirable to delete, mutate or otherwise interrupt the gene encoding WO 99/27107 PCT/US98/24873 -- 4- PurU from the gram-positive microorganism cell in order to reduce the hydrolysis of N10 formyltetrahydrofolate, thereby increasing the formate remaining in the cell. It may also be desirable to increase expression of PurU under certain conditions of cell growth. Furthermore, as illustrated infra, expression of PurU may also be regulated metabolically 5 through the addition of glycine or methionine into the culture media. Accordingly, the present invention provides a method for producing a product in a gram-positive microorganism comprising obtaining a gram-positive microorganism capable of expressing the product and further comprising a mutation in the nucleic acid encoding PurU, said mutation resulting in inhibition of production by said microorganism of PurU 10 activity; and culturing said microorganism under conditions suitable for expression of said product. Based upon the overall sequence homology with Bacillus Def, it appears that gram positive FMD plays a role in modifying initiating methionines. Therefore, modifying the expression of FMD in a gram positive host cell under large scale fermentation conditions 15 may be desirable. Accordingly, the present invention provides a method for increasing the production of a product in a gram positive microorganism which comprises the steps of obtaining a gram-positive microorganism capable of expressing said product; b) modifying the expression of FMD in said microorganism; and c) culturing said microorganism under conditions suitable for expression of said product. 20 The present invention also provides expression vectors and gram-positive microorganims comprising isolated nucleic acid encoding FTAP 1 and/or 2 and/or PurU and/or FMD. The present invention also provides gram-positive microorganisms having a deletion or mutation of part or all of the nucleic acid encoding FTAP 1 and/or 2 and/or PurU and/or FMD. 25 The present invention also provides a method for the detection of B.subtilis FTAP 1, FTAP 2, PurU or FMD polynucleotide homologs which comprises hybridizing part or all of a nucleic acid sequence of B. subtilis FTAP 1, FTAP 2, PurU or FMD with gram-positive microorganism nucleic acid of either genomic or cDNA origin. 30 Brief Description of the Figures Figures 1A-1C shows the nucleic acid SEQ ID NO: 1 and amino acid SEQ ID NO: 2 sequence of FTAP 1 (YRHG). Figures 2A-2C shows the nucleic acid SEQ ID NO: 3 and amino acid sequence SEQ ID NO: 4 of FTAP 2 (YWCJ). 35 Figures 3A-3C shows the nucleic SEQ ID NO: 5 and amino acid SEQ ID NO: 6 of PurU (YKKE). Figures 4A and 4B show the nucleic acid SEQ ID NO: 7 amino acid sequence SEQ ID NO: 8 of FMD (Def).

WO 99/27107 PCT/US98/24873 -- 5- Figure 5 Shows the comparison of growth and pH over time of Bacillus subtilis (BG125) cultures grow in SBG1% with the addition or absence of MOPS buffer and 3 g/l of sodium formate. Figure 6 shows changes in pH with the sequential addition of HCI on SBG1%, 5 SBG1% and 80 mM MOPS, and 3 g/l formate and SBG 1%. Figure 7 shows the comparison of growth over time of Bacillus subtilis (BG125) cultures of SBG1 % with the absence or addition of formate at increasing concentrations. Figure 8 shows the uptake of formate by cultures in Fig 5 measured by HPLC as described in Material and Methods. 10 Figure 9 shows the production of acetic acid by cultures in Fig 5 over time measured by HPLC as described in Material and Methods. Figure 10 shows the uptake of glucose by cultures in Fig 5 measured by HPLC as described in Material and Methods. Figure 11 shows the effect of trimethaprim addition on the growth of Bacillus subtilis 15 in SBG 1% with additives and formate as indicated. Trimethaprim (Drug) was added at Klett 25 where indicated. Figure 12 illustrates an amino acid alignment of FTAP1 (YRHG) with EcopFlz.p1 (which comprises E.coli FocA) SEQ ID NO: 9. Figure 13 illustrates an amino acid alignment of FTAP 2 (YWCJ) with EcopFlz.pl. 20 Figure 14 illustrates an amino acid alignment of E.coli PurU SEQ ID NO: 10 with B.subtilis PurU (YKKE). Figure 15 illustrates a schematic representation of molecules associated with formate transport, utilization and cycling in gram-positive microorganisms. Figure 16 illustrates the effect of the interruption (int.) of yrhG gene on the cell 25 growth of BG125. Cells containing the gene interruption were grown in SBG1% containing 3 g/l formate and kanamycin as indicated. Growth was determined as described in Material and Methods. Control (----) Formate (------ ) ywcJ int. (----0----) ywcJ int. + formate (--A--) ywcJ int. + Kan (- - -1fi-- - ) ywcJ int. + formate + Kan (----- ). Figure 17 illustrates the effect of the interruption (int.) of ywcJ gene on the cell 30 growth of BG125. Cells containing the gene interruption were grown in SBG1% containing 3 g/l formate and kanamycin as indicated. Growth was determined as described in Material and Methods. Control (-0--), formate (------ ), ywcJ int. (----0----), ywcJ int. + formate (--A--), ywcJ int. + Kan (- --- -- ), ywcJ int. + formate + Kan (----- ).

WO 99/27107 PCT/US98/24873 -- 6- Detailed Description of the Invention Definitions As used herein, the genus Bacillus includes all members known to those of skill in the art, including but not limited to B. subtilis, B. /icheniformis, B. lentus, B. brevis, B. 5 stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. coagulans, B. ciculans, B. lautus and B. thuringiensis. The present invention encompasses FTAP 1, FTAP 2, PurU and FMD from gram positive organisms. In a preferred embodiment, the gram-positive organism is a Bacillus. In another preferred embodiment, the gram-positive organism is Bacillus subtilis. As used 10 herein, "B.subtilis FTAP 1, FTAP 2, PurU and FMD" refers to the amino acid sequences shown in Figures 1, 2, 3 and 4, respectively and designated as YRHG, YWCJ, YKKE and DeF, respectively. The present invention encompasses amino acid homologs of the B.subtilis amino acid sequences of FTAP 1, FTAP 2, PurU and FMD, i.e., variations of the amino acid sequences disclosed in Figures 1, 2, 3 and 4, that retain functional capabilities 15 and are referred to herein as, FTAP 1, FTAP 2, PurU and FMD. As used herein, "nucleic acid" refers to a nucleotide or polynucleotide sequence, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be double-stranded or single-stranded, whether representing the sense or antisense strand. As used herein "amino acid" refers to peptide or protein sequences or portions 20 thereof. A "polynucleotide homolog" as used herein refers to a gram-positive microorganism polynucleotide that has at least 80%, at least 85%, at least 90% and at least 95% identity to B.subtilis FTAP 1, FTAP 2, PurU or FMD, or which is capable of hybridizing to B.subtilis FTAP 1 and 2, PurU or FMD under conditions of high stringency. The terms "isolated" or "purified" as used herein refer to a nucleic acid or protein or 25 peptide that is removed from at least one component with which it is naturally associated. In the present invention, an isolated nucleic acid can include a vector comprising the nucleic acid. As used herein, the term "product" refers to any naturally occurring or recombinantly introduced product obtainable from the gram-positive microorganism, e.g. 30 protein, polypeptide, peptide, chemical and includes but is not limited to anti-microbial compounds, antibiotics, antigens, antibodies, surfactant, chemical products and enzymes. A recombinant protein is one which is encoded by nucleic acid which has been introduced into the microorganism. The nucleic acid can be introduced on an expression vector having signals capable of expressing the protein encoded by the introduced nucleic acid or as the nucleic acid can be integrated into the microorganism chromosome. The recombinant protein may be heterologous to the microoganism or homologous to the microorganism. As used herein, the term "heterologous protein" refers to a protein or polypeptide that does not naturally occur in a gram-positive host cell. Examples of heterologous proteins include WO 99/27107 PCT/US98/24873 -- 7enzymes such as hydrolases including proteases, cellulases, amylases, carbohydrases, and lipases; isomerases such as racemases, epimerases, tautomerases, or mutases; transferases, kinases and phophatases. The heterologous gene may encode therapeutically significant proteins or peptides, such as growth factors, cytokines, ligands, 5 receptors and inhibitors, as well as vaccines and antibodies. The gene may encode commercially important industrial proteins or peptides, such as proteases, carbohydrases such as amylases and glucoamylases, cellulases, oxidases and lipases. The gene of interest may be a naturally occurring gene, a mutated gene or a synthetic gene. The term "homologous protein" refers to a protein or polypeptide native or naturally 10 occurring in a gram-positive host cell. The invention includes host cells producing the homologous protein via recombinant DNA technology. The present invention encompasses a gram-positive host cell having a deletion or interruption of the nucleic acid encoding the naturally occurring homologous protein, such as a protease, and having nucleic acid encoding the homologous protein re-introduced in a recombinant form. In 15 another embodiment, the host cell produces the homologous protein. It is well understood in the art that formate may exist in a variety of ionization states depending upon the surrounding media, if in solution, or out of solution from which they are prepared if in solid form. The use of a term, such as, for example, formic acid, to designate such molecules is intended to include all ionization states of the organic molecule referred 20 to. Thus, for example, both "formic acid" and "formate" refer to the same moiety, and are not intended to specify particular ionization states. Description of the Preferred Embodiments 1. Bacillus Formate Transport 25 A growth enhancement phenomenon observed when sodium formate was added to shake flask cultures of Bacillus subtilis revealed information on the mechanism of formate transport into the cell. Total cell density was much higher and the culture was able to maintain its growth rate for a longer period of time. The growth enhancement of formate was correlated with the prevention of the normal drop in pH to below 6.0 during growth in 30 1% SBG medium. Concentrations of sodium formate ranging from 3 g/l (44 mM) to 21 g/l (308 mM) produced a similar effect for overall growth enhancement. However, while 3 g/l sodium formate caused a only a slight lag in initial growth rate, the lag became more pronounced with increasing concentrations of formate. Growth of B. subtilis in 1% SBG was accompanied by the production of acetate, the likely cause of the normal pH drop and as the fall in growth rate. Experiments with MOPS buffer showed that the growth enhancement due to formate was duplicated to a large degree by pH control with a buffer. It was observed that the uptake of formate from the medium began during early WO 99/27107 PCT/US98/24873 -- 8exponential growth and was removed completely before the beginning of stationary phase for both formate and formate plus MOPS flasks. In addition, the formate and the formate plus MOPS flasks did show an enhancement of the production of acetate compared to the control and the control plus MOPS flasks. Despite the higher concentration of acetic acid, 5 the pH of the formate flask did not fall below 6.4. The rate of glucose uptake was identical in the formate, formate plus MOPS, and MOPS flasks which suggests that the increased production of acetate by formate is linked to some step in glucose metabolism and not glucose transport. It appears that the control of pH by formate is due to a symport transport of formate into the cell with the removal of protons from the media. Studies using 10 trimethaprim shown in the Examples suggest that the transported formate requires tetrahydrofolate synthesis to prevent a growth rate slow down. II. FTAP 1 and 2, PurU and FMD sequences The FTAP 1, FTAP 2, PurU and FMD polynucleotides having the sequences as 15 shown in the Figures encode Bacillus subtilis FTAP 1, FTAP 2, PurU and FMD. As will be understood by the skilled artisan, due to the degeneracy of the genetic code, a variety of polynucleotides can encode Bacillus subtilis FTAP 1, FTAP 2, PurU and FMD. The present invention encompasses all such polynucleotides. The DNA may be obtained by standard procedures known in the art from, for example, 20 cloned DNA (e.g., a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from a desired cell. (See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. 1, 11.) A preferred source is genomic 25 DNA. Nucleic acid sequences derived from genomic DNA may contain regulatory regions in addition to coding regions. Whatever the source, the isolated FTAP 1, FTAP 2, PurU or FMD gene should be molecularly cloned into a suitable vector for propagation of the gene. In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific 3o sites using various restriction enzymes. Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography. 35 Once the DNA fragments are generated, identification of the specific DNA fragment containing the FTAP 1, FTAP 2, PurU or FMD may be accomplished in a number of ways. For example, a FTAP 1, FTAP 2, PurU or FMD gene of the present invention or its specific RNA, or a fragment thereof, such as a probe or primer, may be isolated and labeled and WO 99/27107 PCT/US98/24873 -- 9then used in hybridization assays to detect a generated FTAP 1, FTAP 2, PurU or FMD gene. (Benton, W. and Davis, R., 1977, Science 196:180; Grunstein, M. And Hogness, D., 1975, Proc. Nati. Acad. Sci. USA 72:3961). Those DNA fragments sharing substantial sequence similarity to the probe will hybridize under stringent conditions. 5 The present invention encompasses FTAP 1, FTAP 2, PurU and FMD polynucleotide homologs encoding gram-positive microorganism FTAP 1, FTAP 2 PurU and FMD respectively, which have at least 80%, or at least 85%, or at least 90% or at least 95% identity to FTAP 1, FTAP 2, PurU and FMD obtainable from B.subtilis as long as the homolog encodes a protein that retains a functional activity. 10 Gram-positive microorganism polynucleotide homologs of B. subtilis can be identified through nucleic acid hybridization of gram-positive microorganism nucleic acid of either genomic of cDNA origin. The polynucleotide homolog sequence can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments disclosed in the Figures. Accordingly, the present invention provides a method for the 1s detection of B.subtilis FTAP 1, FTAP 2, PurU or FMD polynucleotide homologs which comprises hybridizing part or all of a nucleic acid sequence of B. subtilis FTAP 1, FTAP 2, PurU or FMD with gram-positive microorganism nucleic acid of either genomic or cDNA origin. Also included within the scope of the present invention are gram-positive 20 microorganism polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of B.subtilis FTAP 1, FTAP 2, PurU or FMD under conditions of intermediate to maximal stringency. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San 25 Diego CA) incorporated herein by reference, and confer a defined "stringency" as explained below. "Maximum stringency" typically occurs at about Tm-5 0 C (5 0 C below the Tm of the probe); "high stringency" at about 5 0 C to 10 0 C below Tm; "intermediate stringency" at about 10*C to 200C below Tm; and "low stringency" at about 20 0 C to 250C below Tm. As will be 30 understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs. The term "hybridization" as used herein shall include "the process by which a strand as of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY).

WO 99/27107 PCT/US98/24873 -- 10 The process of amplification as carried out in polymerase chain reaction (PCR) technologies is described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY). A nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides from B. subtilis FTAP 5 1, FTAP 2, PurU or FMD preferably about 12 to 30 nucleotides, and more preferably about 20-25 nucleotides can be used as a probe or PCR primer. The B.subtilis amino acid sequences FTAP 1, FTAP 2, PurU and FMD (shown in Figures 1, 2, 3 and 4 respectively) were identified via a FASTA search of Bacillus subtilis genomic nucleic acid sequences. The present invention 10 encompasses gram positive microorganism amino acid variants of B. subtilis FTAP 1, FTAP 2, PurU and FMD that are at least 80% identical, at least 85% identical, at least 90% identical and at least 95% identical to B. subtilis FTAP 1, FTAP 2, PurU and FMD as long as the amino acid sequence variant retains a functional activity. 15 Ill. Expression Systems The present invention provides host cells, expression methods and systems for the enhanced production and secretion of heterologous or homologous proteins in gram positive microorganisms. In one embodiment, a host cell is genetically engineered to have a deletion or mutation in the gene encoding a gram-positive FTAP 1, FTAP 2, PurU or FMD 20 such that the respective activity is deleted. In another embodiment of the present invention, a gram-positive microorganism is genetically engineered to increase the levels of FTAP 1, FTAP2, Pur2 or FMD, or other molecules associated with formate transport, utilization or cycling. 25 Inactivation of FTAP 1 or 2 or PurU in a host cell Producing an expression gram-positive microorganism host cell incapable of producing the naturally occurring formate associated protein necessitates the replacement and/or inactivation of the naturally occurring gene from the genome of the host cell. In a preferred embodiment, the mutation is a non-reverting mutation. 30 One method for mutating nucleic acid encoding a gram-positive formate associated protein is to clone the nucleic acid or part thereof, modify the nucleic acid by site directed mutagenesis and reintroduce the mutated nucleic acid into the cell on a plasmid. By homologous recombination, the mutated gene may be introduced into the chromosome. In the parent host cell, the result is that the naturally occurring nucleic acid and the mutated as nucleic acid are located in tandem on the chromosome. After a second recombination, the modified sequence is left in the chromosome having thereby effectively introduced the mutation into the chromosomal gene for progeny of the parent host cell.

WO 99/27107 PCTIUS98/24873 -- 11 - Another method for inactivating the activity is through deleting the chromosomal gene copy. In a preferred embodiment, the entire gene is deleted, the deletion occurring in such as way as to make reversion impossible. In another preferred embodiment, a partial deletion is produced, provided that the nucleic acid sequence left in the chromosome is too 5 short for homologous recombination with a plasmid encoded FTAP 1, FTAP 2, PurU and FMD gene. In another preferred embodiment, nucleic acid encoding the catalytic amino acid residues are deleted. Deletion of the naturally occurring gram-positive microorganism formate transport, utilization and cycling associated protein can be carried out as follows. A gene encoding a 10 formate associated protein including its 5' and 3' regions is isolated and inserted into a cloning vector. The coding region of the gene is deleted form the vector in vitro, leaving behind a sufficient amount of the 5' and 3' flanking sequences to provide for homologous recombination with the naturally occurring gene in the parent host cell. The vector is then transformed into the gram-positive host cell. The vector integrates into the chromosome 15 via homologous recombination in the flanking regions. This method leads to a gram positive strain in which the formate associated gene has been deleted. The vector used in an integration method is preferably a plasmid. A selectable marker may be included to allow for ease of identification of recombinant microorgansims. Additionally, as will be appreciated by one of skill in the art, the vector is preferably one 20 which can be selectively integrated into the chromosome. This can be achieved by introducing an inducible origin of replication, for example, a temperature sensitive origin into the plasmid. By growing the transformants at a temperature to which the origin of replication is sensitive, the replication function of the plasmid is inactivated, thereby providing a means for selection of chromosomal integrants. Integrants may be selected for 25 growth at high temperatures in the presence of the selectable marker, such as an antibiotic. Integration mechanisms are described in WO 88/06623. Integration by the Campbell-type mechanism can take place in the 5' flanking region of the protease gene, resulting in a protease positive strain carrying the entire plasmid vector in the chromosome in the formate associated protein locus. Since 30 illegitimate recombination will give different results it will be necessary to determine whether the complete gene has been deleted, such as through nucleic acid sequencing or restriction maps. Another method of inactivating the naturally occurring gene is to mutagenize the chromosomal gene copy by transforming a gram-positive microorganism with 35 oligonucleotides which are mutagenic. Alternatively, the chromosomal gene can be replaced with a mutant gene by homologous recombination.

WO 99/27107 PCT/US98/24873 -- 12 - The present invention encompasses host cells having additional protease deletions or mutations, such as deletions or mutations in apr, npr, epr, mpr and others known to those of skill in the art. 5 IV. Production of FTAP1, FTAP2, PurU or FMD For production of FTAP1, FTAP2, PurU or FMD in a host cell, an expression vector comprising at least one copy of nucleic acid encoding a gram-positive microorganism FTAP 1, FTAP 2, PurU or FMD, and preferably comprising multiple copies, is transformed into the host cell under conditions suitable for expression of the protein In accordance with the 10 present invention, polynucleotides which encode a gram-positive microorganism FTAP 1, FTAP 2, PurU FMD or fragments thereof, or fusion proteins or polynucleotide homolog sequences that encode amino acid variants of B.subtilis FTAP 1, FTAP 2, PurU or FMD that retain activity may be used to generate recombinant DNA molecules that direct their expression in host cells. In a preferred embodiment, the gram-positive host cell belongs to 15 the genus Bacillus. In another preferred embodiment, the gram positive host cell is B. subtilis. As will be understood by those of skill in the art, it may be advantageous to produce polynucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular gram-positive host cell (Murray E et al (1989) Nuc Acids Res 17:477-508) 20 can be selected, for example, to increase the rate of expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence. Altered FTAP 1, FTAP 2, PurU or FMD polynucleotide sequences which may be used in accordance with the invention include deletions, insertions or substitutions of 25 different nucleotide residues resulting in a polynucleotide that encodes the same or a functionally equivalent FTAP 1, FTAP 2, PurU or FMD homolog, respectively. As used herein a "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent. As used herein an "insertion" or "addition" is that change in a nucleotide or amino 30 acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring protein. As used herein "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. The encoded protein may also show deletions, insertions or substitutions of amino as acid residues which produce a silent change and result in a functionally FTAP 1, FTAP 2, PurU or FMD variant. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the variant retains the ability to modulate WO 99/27107 PCTIUS98/24873 -- 13 secretion. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine, 5 phenylalanine, and tyrosine. The FTAP 1, FTAP 2, PurU or FMD polynucleotides of the present invention may be engineered in order to modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, eg, site-directed mutagenesis to insert new restriction sites, to alter 10 glycosylation patterns or to change codon preference, for example. In one embodiment of the present invention, a gram-positive microorganism FTAP 1, FTAP 2, PurU or FMD polynucleotide may be ligated to a heterologous sequence to encode a fusion protein. A fusion protein may also be engineered to contain a cleavage site located between the FTAP1, FTAP2, PurU or FMD nucleotide sequence and the 15 heterologous protein sequence, so that the protein may be cleaved and purified away from the heterologous moiety. V. Vector Sequences Expression vectors used in expressing the proteins of the present invention in 20 gram-positive microorganisms comprise at least one promoter associated with a protein selected from the group consisting of FTAP 1, FTAP 2, PurU and FMD, which promoter is functional in the host cell. In one embodiment of the present invention, the promoter is the wild-type promoter for the selected protein and in another embodiment of the present invention, the promoter is heterologous to the protein, but still functional in the host cell. In 25 one preferred embodiment of the present invention, nucleic acid encoding the protein is stably integrated or otherwise stably maintained in the microorganism genome. In a preferred embodiment, the expression vector contains a multiple cloning site cassette which preferably comprises at least one restriction endonuclease site unique to the vector, to facilitate ease of nucleic acid manipulation. In a preferred embodiment, the 30 vector also comprises one or more selectable markers. As used herein, the term selectable marker refers to a gene capable of expression in the gram-positive host which allows for ease of selection of those hosts containing the vector. Examples of such selectable markers include but are not limited to antibiotics, such as, erythromycin, actinomycin, chloramphenicol and tetracycline. 35 VI. Transformation A variety of host cells can be used for the production of FTAP 1, FTAP 2, PurU and FMD including bacterial, fungal, mammalian and insects cells. General transformation WO 99/27107 PCT/US98/24873 -- 14 procedures are taught in Current Protocols In Molecular Biology vol. 1, edited by Ausubel et al., John Wiley & Sons, Inc. 1987, chapter 9 and include calcium phosphate methods, transformation using DEAE-Dextran and electroporation. Plant transformation methods are taught in Rodriquez (WO 95/14099, published 26 may 1995). 5 In a preferred embodiment, the host cell is a gram-positive microorganism and in another preferred embodiment, the host cell is Bacillus. In one embodiment of the present invention, nucleic acid encoding one or more proteins of the present invention is introduced into a host cell via an expression vector capable of replicating within the Bacillus host cell. Suitable replicating plasmids for Bacillus are described in Molecular Biological Methods for 10 Bacillus, Ed. Harwood and Cutting, John Wiley & Sons, 1990, hereby expressly incorporated by reference; see chapter 3 on plasmids. Suitable replicating plasmids for B. subtilis are listed on page 92. In another embodiment, nucleic acid encoding a protein of the present invention is stably integrated into the microorganism genome. Preferred host cells are gram-positive 15 host cells. Another preferred host is Bacillus. Another preferred host is Bacillus subtilis. Several strategies have been described in the literature for the direct cloning of DNA in Bacillus. Plasmid marker rescue transformation involves the uptake of a donor plasmid by competent cells carrying a partially homologous resident plasmid (Contente et al., Plasmid 2:555-571 (1979); Haima et al., Mol. Gen. Genet. 223:185-191 (1990); Weinrauch et al., J. 20 Bacteriol. 154(3):1077-1087 (1983); and Weinrauch et al., J. Bacteriol. 169(3):1205-1211 (1987)). The incoming donor plasmid recombines with the homologous region of the resident "helper" plasmid in a process that mimics chromosomal transformation. Transformation by protoplast transformation is described for B. subtilis in Chang and Cohen, (1979) Mol. Gen. Genet 168:111-115; for B.megaterium in Vorobjeva et al., 25 (1980) FEMS Microbiol. Letters 7:261-263; for B. amyloliquefaciens in Smith et al., (1986) Apple. and Env. Microbiol. 51:634; for B.thuringiensis in Fisher et al., (1981) Arch. Microbiol. 139:213-217; for B.sphaericus in McDonald (1984) J. Gen. Microbiol. 130:203; and B.larvae in Bakhiet et al., (1985) 49:577. Mann et al., (1986, Current Microbiol. 13:131 135) report on transformation of Bacillus protoplasts and Holubova, (1985) Folia Microbiol. 30 30:97) disclose methods for introducing DNA into protoplasts using DNA containing liposomes. VII. Identification of Transformants Whether a host cell has been transformed with a mutated or a naturally occurring 35 gene encoding a gram-positive FTAP 1, FTAP 2, PurU or FMD, detection of the presence/absence of marker gene expression can suggests whether the gene of interest is present However, its expression should be confirmed. For example, if the nucleic acid encoding a FTAP1, FTAP2, PurU or FMD is inserted within a marker gene sequence, WO 99/27107 PCTIUS98/24873 -- 15 recombinant cells containing the insert can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with nucleic acid encoding the FTAP1, FTAP2, PurU or FMD under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the FTAP 5 1, FTAP 2, PurU and FMD as well. Alternatively, host cells which contain the coding sequence for a FTAP 1, FTAP 2, PurU and FMD and express the protein may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include 10 membrane-based, solution-based, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein. The presence of the polynucleotide sequence can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of B.subtilis FTAP 1, FTAP 2, PurU or FMD. 15 Vill. Secretion of Recombinant Proteins Means for determining the levels of secretion of a heterologous or homologous protein in a gram-positive host cell and detecting secreted proteins include, using either polyclonal or monoclonal antibodies specific for the protein. Examples include enzyme 20 linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). These and other assays are described, among other places, in Hampton R et al (1990, Serological Methods, a Laboratory Manual, APS Press, St Paul MN) and Maddox DE et al (1983, J Exp Med 158:1211). A wide variety of labels and conjugation techniques are known by those skilled in 25 the art and can be used in various nucleic and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting specific polynucleotide sequences include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the nucleotide sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are 30 commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides. A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those as radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; WO 99/27107 PCTIUS98/24873 -- 16 - 4,275,149 and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567 and incorporated herein by reference. IX. Purification of Proteins 5 Gram positive host cells transformed with polynucleotide sequences encoding heterologous or homologous protein may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant gram-positive host cell comprising a FTAP 1, FTAP 2, PurU and FMD of the present invention will be secreted into the culture media. Other recombinant constructions 10 may join the heterologous or homologous polynucleotide sequences to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12:441-53). Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals is (Porath J (1992) Protein Expr Purif 3:263-281), protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and the heterologous protein can be used to facilitate purification. 20 X. Uses of The Present Invention FTAP 1, FTAP 2, PurU and FMD and Genetically Engineered Host Cells The present invention provides genetically engineered gram-positive microorganisms comprising preferably non-revertable mutations or deletions in the naturally 25 occurring gene encoding FTAP 1, FTAP 2, PurU or FMD such that activity is diminished or deleted altogether. In another embodiment, the microorganism is further genetically engineered to produce a recombinant protein or polypeptide. In a preferred embodiment the host cell is a Bacillus. In another preferred embodiment, the host cell is a Bacillus subtilis. 30 In an alternative embodiment, a host cell is genetically engineered to produce a gram-positive FTAP 1, FTAP 2, PurU or FMD. In a preferred embodiment, the host cell is grown under large scale fermentation conditions, the FTAP 1, FTAP 2, PurU or FMD is isolated and/or purified. 3s FTAP 1, FTAP 2, PurU and FMD Polynucleotides A B.subtliis FTAP1, FTAP2, PurU or FMD polynucleotide, or any part thereof, provides the basis for detecting the presence of gram-positive microorganism polynucleotide homologs through hybridization techniques and PCR technology.

WO 99/27107 PCT/US98/24873 -- 17 - Accordingly, one aspect of the present invention is to provide for nucleic acid hybridization and PCR probes which can be used to detect polynucleotide sequences, including genomic and cDNA sequences, encoding gram-positive FTAP 1, FTAP 2, PurU or FMD or portions thereof. 5 All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention 10 as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims. 15 EXAMPLES Materials and Methods Bacterial strains and media The Bacillus subtilis strain used was a derivative of 1168 called BG125 (hisAl thr5 trpC2) provided by J. A. Hoch. The strain was grown on Luria-Bertani agar (LA. 1% SBG 20 medium contained the following: soytone; Difco, 10g/L, glucose; Sigma, 10g/L, yeast extract; Difco, 5g/L, NaCl, Norton, 10g/L, pH 7.0. 1% SBG plus MOPS, Sigma, contained 80 mM MOPS pH 7.0. Sodium formate, EM Science, at various concentrations was added to 1% SBG where indicated. The pH of all media was adjusted to 7 with NaOH. The growth medium for the bactericidal tests of formate was SBG1 % supplemented with 50 mM 25 MES, Sigma, 50 mM HEPES, Sigma, followed by pH adjustment to the pH value indicated with either NaOH or HCL. Formic acid was then added to a final concentration of 50 mM which resulted in no change in the pH of the growth medium. MM294 competent cells (Ausubel et al. 1992, Short Protocols in Molecular Biology. John Wiley and Sons, New York) were used for plasmid construction and propagation. LB broth and agar were used 30 for growing MM294 cells and were supplemented with 50 ug/ml carbenicillin for selection. BG125 was grown on LB agar or in LB liquid medium supplemented with 10 pg/ml of kanamycin for selection. Trimethaprim was dissolved in 50% ethanol and added to a final concentration of 50 ug/ml where indicated when the growth had reached a Klett reading between 20-30 35 units. The additions for trimethaprim experiments were added at the following final concentrations: 10 ug/ml glycine, 10 ug/mI methionine, 50 ug/mI thymidine, 20 ug/ml adenosine, and 20 ug/mI guanosine.

WO 99/27107 PCT/US98/24873 -- 18 - DNA manipulations Chromosomal DNA extraction, plasmid DNA extraction, PCR clean-up and DNA fragment extraction from gels were performed using the QIAGEN Blood & Cell Culture DNA Kit, QlAprep Spin Miniprep Kit, QlAquick PCR Purification Kit and the QlAquick Gel 5 Extraction Kit respectively. Enzymatic amplification of DNA by PCR was according to standard protocol. Restriction endonuclease digestion and ligation of DNA were performed as specified by the manufacturers. The DNA sequence identity search for yrhG (FTAP 1) and ywcJ (FTAP 2) was performed using the GCG software package (Genetics Computer Group). 10 Plasmid construction The cloning vector used in this study was pUC/Ts/Kan, an E. co/i-B. subtilis shuttle vector. The plasmid consists of the pUC19 plasmid, the temperature sensitive origin of replication from the Staphylcoccus aureus plasmid derivative pE194Ts (Fleming et al. 1995, 15 App. Env. Microb. 61:3775-3780), and the kanamycin gene from Streptococcus faecalis (Trieu-Cuot et al. 1983, Gene 23: 331-341). A 0.438-Kb DNA segment of the yrhG gene was amplified from B. subtilis BG125 chromosomal DNA by PCR using Taq DNA polymerase (Boehringer Mannheim), and oligonucleotide primers GCGCGCGGATCCGTAATTGGCGATCTTCCGAAAGAATGG (SEQ 20 ID NO: 11) and GCGCGCCTGCAGGGGAACCAGATGCCAAGGATTTTTCC (SEQ ID NO: 12) (the BamH/ and Pst/ sites are underlined). The PCR product was digested with BamHI and Pst/ and ligated with the 5.3-Kb BamH/-Pst/ fragment from plasmid pUC/Ts/Kan to construct the yrhG-homologue interruption plasmid pTRANS1. Plasmid pTRANS2 was constructed in a similar way by amplifying a 0.543-Kb DNA of the ywcJ gene using Taq 25 DNA polymerase and oligonucleotide primers GCGCGCGGATCCTTGGTTTTGGCATTACAGCCGC (SEQ ID: 13) and GCGCGCCTGCAGAGGGTGCTCGATCAAAAGCGAGATGG (SEQ ID NO: 14) (the BamHI and Pst/ sites are underlined). The PCR product was digested with BamH/ and Pst/ and ligated with the 5.3-Kb BamHI-Pst/ fragment from plasmid pUC/Ts/Kan to construct the 30 ywcJ-homologue interruption plasmid. DNA sequencing was performed on both the pTRANS1 and pTRANS2 interuption plasmids to verify the presence of the correct PCR generated fragment using an Applied Biosystems 373A DNA sequencer. The sequencing primers used were the mp19/pUC19 24-mer reverse sequencing primer and the mpl9/pUC19 24-mer sequencing primer from New England Biolabs.

WO 99/27107 PCT/US98/24873 -- 19 - Introduction of the gene interruptions into B. subtilis. To construct B. subtilis strains containing an interruption of either the yrhG or ywcJ genes, pTRANS1 and pTRANS2 were transformed separately into BG125 by protoplast transformation as described (Chang et al. 1979, Mol. Gen. Genet. 168:111-115) and plated 5 on protoplast regeneration medium with 200 ug/ml kanamycin at 300C. Resulting kanamycin resistant transformants were grown overnight in LB liquid medium containing kanamycin at 450C. Integrants were plated and then colony purified on LB plates containing kanamycin at 450C. Isolated colonies were then frozen in LB liquid medium plus 30% glycerol at -700C for preservation. 10 Growth conditions. Prior to shake flask experiments BG125 was grown from frozen stocks onto LB agar and grown overnight at 370C. Cells were removed from the plates to 6 mis of SBG1% in test-tubes and grown at 370C for three hours. 0.2 mIs of the seed culture was used to 1s inoculate a pre-warmed 300 ml nephlometer flask containing 20 mls of the appropriate media. Flasks were incubated at 370C (except where indicated) and 300 rpm in a New Brunswick Scientific Shaker. At the indicated time points, the amount of cell growth was determined by a Klett-Summerson Photoelectric Colorimeter, the pH of the flask was taken using a Corning pH/iometer, and 1.25 mis was removed for further processing. The 20 sample was spun in an eppendorf microfuge and 1 ml of supernatant was removed and mixed with 30 pls of perchloric acid HPLC analysis. The remaining supernatant was saved for glucose analysis. All samples were stored at -700C until analysis. Medium pH titrations were performed by the stepwise addition of HCI followed by pH measurement. The bactericidal tests of pH and formate on B. subitlis were carried out by growing BG125 as 25 described above in SBG1% to a density of 5 x 106 cfu/ml. The cells were then adjusted to a concentration of 5 x 104 cfu/ml with buffered SBG1% adjusted to the pH indicated, with and without 50 mM formate. Cultures were then incubated at 370C with shaking for 3 hours. Samples were taken at 0, 1 2 and 3 hours, serially diluted and plated to LB at 370C for determination of cell viability. 30 Analysis of metabolic by-products. One ml of acid treated culture supernatant was filtered through a 0.2 4m membrane filter. The concentrations of the metabolic by-products was determined with high performance liquid chromatography (HPLC). A Shodex SH1011 cation-exchange column as heated to 500 C was used. The solvent used was 5 mM sulfuric acid (H 2

SO

4 ) at a flow rate WO 99/27107 PCT/US98/24873 -- 20 of 0.4 ml./min. The HPLC system consisted of a Waters model 510 pump with a pulse dampener SSI model LP-21, an Refractive Index (RI) detector Waters 410 Differential Refactometer model, a Waters autoinjector 712 WISP model injecting 20 [tL injections per sample. The HPLC was interfaced with a Millennium 2.15.01 HPLC control system for 5 mobile phase flow control, integration, and data collection and storage. To identify different peaks, standards were run and compared to the peaks in the samples. The standards run were: acetoin, acetic acid, 2,3-butanediol, butyric acid, citric acid, formic acid, ethanol, fumaric acid, malic acid, glycerol, lactic acid, propionic acid, and pyruvic acid all from Sigma. 10 Example I Example I illustrates that formate addition increases growth by pH control. BG125 was grown as described in Materials and Methods. In 1% SBG (pH 7) medium with and without 3 g/I (44 mM) sodium formate, the addition of sodium formate 15 resulted in more total growth compared to the control flask and it also acted to prevent the fall of shake flask pH below 6.5 while the control flask pH dropped to 5.5 (Fig. 5). With a pKa of 3.73, formate should have little buffering activity at a starting pH of 7. To rule out any buffer effects of our media, a pH titration experiment was performed with 1% SBG, and 1% SBG containing either 3 g/l sodium formate or 80 mM MOPS. Fig. 6 shows that in 1% 20 SBG, and 1% SBG with sodium formate there is little buffering activity down to pH 5.0. 1% SBG medium containing MOPS (pKa 7.20) showed buffering activity in the expected range. When BG 125 was grown in SBG1% containing 80mM MOPS which prevented a pH drop below 6.3, the growth of the strain was near the levels of the formate containing flask (Fig. 5). In addition, a flask containing MOPS plus formate grew almost identically to the MOPS 25 flask (Fig. 5).

WO 99/27107 PCT/US98/24873 -- 21 - Example II Example 11 illustrates that increasing concentrations of formate cause a lag in initial growth rate. When using 3 g/l mN sodium formate, a slight lag in the initial growth rate was 5 observed. To further investigate this lag, the growth of BG125 with higher concentrations of sodium formate (up to 21 g/l) was tested. It was found that there was a correlation between increasing concentrations of formate and the duration of the initial lag period (Fig. 7). All the cultures tested did resume growth after the lag period at similar rates and reached higher densities than the control flask. 10 Example Ill Example Ill illustrates that formate addition results in increased acetate production. To further study the effect of formate on growth of BG125 we also studied the production of various organic by-products and the utilization of glucose in the shake flasks 15 of Figure 5. Fig. 8 shows that the uptake of formate from the medium began during early exponential growth and was removed completely before the beginning of stationary phase for both the formate and formate plus MOPS flasks (Fig. 5). Measurement of acetate levels (Fig. 9) revealed the production of large amounts of this compound in all flasks which is likely the cause of the drop in pH during growth in SBG1%; however, the amounts of 20 acetate produced did vary. The control flask, 1% SBG only, slowed the production of acetate first, and reached about 1.5 g/L. The flask buffered with MOPS reached close to 2 g/L of acetate at a faster rate than the control. The two flasks containing formate continued to produce acetate for the longest period and reached between 2.5 and 3 g/L. 25 Example IV Example IV illustrates that glucose uptake was not enhanced by formate. When glucose levels were examined during the experiment (Fig. 10) the MOPS, formate, and MOPS plus formate flasks used glucose at the same rate until it was undetectable by 450 minutes. The control flask utilized glucose at the same rate until 250 30 minutes when the uptake slowed down and stopped at 6 g/L. Example V Example V shows that trimethaprim addition slows growth in the presence of formate. 35 To study the effect of trimethaprim, a tetrahydrofolate synthesis inhibitor, we performed an experiment where we added trimethaprim to flasks containing SBG1%, SBG1% plus formate plus growth additives and a control containing SBG1% plus growth additives. The effect of ethanol used to dissolve the trimethaprim was also tested. Fig. 11 WO 99/27107 PCT/US98/24873 -- 22 shows that the addition of trimethaprim had an inhibitory effect on the growth of B. subtilis in SBG1% medium compared to growth in SBG1% alone. The addition of additives to supplement pathways dependent on tetrahydrofolate to a flask containing trimethaprim partially restored the growth of the strain. When formate was added to a flask containing s trimethaprim and the growth enhancing additives, the rate of growth was then significantly reduced, but still above that of the flask with trimethaprim alone. Ethanol did not have any effect on growth. Example VI 10 Formate enhances the bactericidal effect of low pH on B. subtilis cultures. In order to determine if any of the observed effects of formate at pH 7.0 such as the B. subtilis growth lag involved lethal toxicity to a portion of the cell population, we examined the effect of formate on cell viability at a culture pH of 7 and lower. With a pKa of 3.75, we expected formate to be toxic near this pH. Cultures of BG125 were inoculated into 15 buffered SBG1% with and without 50 mM formate at pH 3.6, 4.0, 4.6 and 7.0. The results showed that the cultures with and without formate lost complete viability within two hours of incubation at pH 3.6. After one hour at pH 3.6, the percent of survivors based on the initial titer was 1.8 % while the addition of formate consistently decreased the percent survivors to an average of 0.13 %. Incubation at pH 4.0 without formate resulted in a lower loss of 20 viability than pH 3.6, reaching 38 % survivors by 3 hours of incubation. Formate increased the loss of viability at pH 4.0 down to 1.2 % survivors by 3 hours. Cultures incubated at pH 4.6 showed no decline in viability with or with out formate. Incubation at pH 7.0 also showed no decline of viability and a increase of cell count suggests that some growth was taking place as expected for this concentration of formate. 25 These results suggest that a gram-positive microorganism fermentation will need to be pH controlled and should not fall below pH 4.6 if formic acid is produced during the culture. Example VI1 30 Homologues to FTAP 1 and FTAP 2 Homologues to FTAP 1 (YrhG) and FTAP 2 (YwcJ) are shown in Tables 1A and 1B. All the homologues found indicated that YrhG and YwcJ are related to proteins involved in transport of formate or other small molecules. YrhG and YwcJ are predicted to be hydrophobic proteins of similar size bearing multiple transmembrane regions. 35 WO 99/27107 PCT/US98/24873 -- 23 - Example VIII Example VIII illustrates the effect that an interruption of the gene encoding FTAP 1 or FTAP 2 had on the growth of Bacillus cells, illustrated in Figures 16 and 17, respectively. For both genes, PCR primers were constructed to amplify an internal region of the 5 genes for gene interruption. These internal fragments were cloned into a replicating plasmid with a temperature sensitive origin of replication for Bacillus. When transformed into the B. subtilis test strain, the plasmid was maintained by antibiotic selection of plasmid markers. Upon temperature upshift in the presence of antibiotic, clones were obtained in 10 which the plasmid has integrated via the region of homology into the chromosome of the Bacillus. This resulted in the interruption of the genes being tested which was maintained by growing the cells above the replication origin activity temperature in the presence of antibiotic. The integrants were tested in shake flasks containing 1%SBG, antibiotic, and with and with out formate. The presence of antibiotic alone on the integrants was tested 15 and had no effect on growth. The integrants were tested against control flasks containing the strain without the plasmids. The results showed that the interruption of each genes had an effect on growth only when formate was added. The interruption of YrhG reduced the normal growth enhancement effect of formate by half. These could be explained by a decrease in the 20 uptake of formate due to the interruption. The interruption of YwcJ (FTAP 2)resulted in a toxic effect which caused a decline of growth well below growth of the control strain with out formate. It thus appears that each gene has a role in formate transport or utilization. Various other examples and modifications of the foregoing description and examples will be apparent to a person skilled in the art after reading the disclosure without 25 departing from the spirit and scope of the invention, and it is intended that all such examples or modifications be included within the scope of the appended claims. All publications and patents referenced herein are hereby incorporated by reference in their entirety.

WO 99/27107 PCTIUS98/24873 -- 24 - r-O 0 0 -1 0 0 -'.4 .14 cn -4 A -4 CN$ 4 $4 4 $4 0 0) a)H 0) 0 *.4) Ln -W -W r a _awl .4.1$ '0 u U '.0 H U U 0 :s c,4~ r- i ( N C * (i (CLn $4 4.) m ll m $4 m m 0~ (d 0) .0' .0 0 0) mc' N~ -- 4C ) ~ 0 cj. r, .. Lna) 00u rH. 0 .. N , N.. -4 0) al 0~ o nr- m r- m u m 0-11 ONr- m r- m a' G)O 41 9 H W 1H H H -4 Hm w H H1- 1H H1H H m 0 41 w 0 a) .14 4 > 0)0 ~444 4-i o 0o 4J 3: 0 U -4 CN0 4J z~ a) '0 CD . a.) ___m 0 ., a) Cco w4-)$ 0 L 0 l 0 0 .1-4 04__ U) 0 - wlCl C) >4 4 0 HD $44 N 0- *) 0 0, o r - Ln m r E Q '0 $40CN4 C N CNz C N N 4J C o : r AU - o C 0) -a) $4( 4 4 $ w m *CD)( D HJ a) r. a a a' N) a uQ 4J a )04 - a 0 a)0 a) 0 -) 0 - ) 0ra) 0 a) 0 ) Q r C: $4 4J $ 4 0 4 4J $J 4 4J $40 CL0 $4 I pH a) r= ~l4C E 4 QE 0$ Q..~) 4W 4C04 04C: 0 40 0) >0 0 0P40 ) 4 0$40 -4$4 0-4 4 0$44$ wi$ FX r- 0-P4 '0 04 44 .4Z4- Z N4-4 N 00 ( WO 99/27 107 PCTIUS98/24873 -- 25 r-O 0 0 H. 0 * 0 o .,1 AH rT m -4 - .- 1 (NL$4 $-I4 0 $4 0) *.) 4) -'.) 4) 04 kD U 0 ID -4 U 0 L):0 C,4 rdr- d CN *a U-) i-P 01 *O *O'l 0 m2 *()N m-C' *C Z (3) 44 ~ ) '(n -Am - N0% c)) .1 ( 0 ON r'-) oll m )(1N ) a) 0 ON oo r- 0or-o 0) O -1 CYNr- N - ON Cr- 0) (I 4-) m 0 >4 4-4 0 (N '.0 4 4JC 431 Li1 -'-4 -H) (N >1 -4. 0 l -4 ) 04 z ' 4 (N4 a) L-- N LA % 14 C4 C N N0" 4 4J (a ( -- -A U0U1mL)z 0 - 0) C.) -4 0 rA 4 4 4 4 ) 4) J 4J (1 C)a 4 )0 ) -4a)0 - 40 ,1a 0 ) 0 -0Q a a) >i0 00 $ 0)W 0$ 4 40-4$ l0W w 0 U 440 r-0 - JP 0 4444 r .4 4Z4) 44 ] 4- 4r

Claims (31)

1. A method for producing a product in a gram-positive microorganism comprising: a) obtaining a microorganism capable of expressing the product, said microorganism comprising either one or both of i) formate transport associated protein 1 (FTAP 1) and ii) formate transport associated protein 2 (FTAP 2); and b) culturing said microorganism in the presence of formate and under conditions suitable for production of said product.

2. The method of Claim 1 wherein said product is a recombinant protein.

3. The method of Claim 2 wherein said recombinant protein is homologous to said microorganism.

4. The method of Claim 2 wherein said recombinant protein is heterologous to said microorganism.

5. The method of Claim 1 wherein said gram-positive organism is a Bacillus.

6. The method of Claim 5 wherein said Bacillus includes B. subtilis, B. icheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. coagulans, B. circulans, B. lautus and Bacillus thuringiensis.

7. The method of Claim 2 wherein said recombinant protein includes hormones, enzymes, growth factor and cytokine.

8. The method of Claim 7 wherein said protein is an enzyme.

9. The method of Claim 8 wherein said enzyme includes protease, lipase, amylase, pullulanase, cellulase, glucose isomerase, laccase and a protein disulfide isomerase.

10. The method of Claim 1 wherein said FTAP 1 has the amino acid sequence as shown in Figure 1. WO 99/27107 PCT/US98/24873 -- 27 -

11. The method of Claim 1 wherein said FTAP 2 has the amino acid sequence as shown in Figure 2.

12. A method for producing a product in a gram-positive microorganism comprising: a) obtaining a gram-positive microorganism capable of expressing the product and further comprising a mutation in the nucleic acid encoding PurU, said mutation resulting in inhibition of production by said microorganism of PurU activity; and b) culturing said microorganism under conditions suitable for production of said product.

13. The method of Claim 12 wherein said product is a recombinant protein.

14. The method of Claim 13 wherein said recombinant protein is homologous to said gram-positive microorganism.

15. The method of Claim 13 wherein said recombinant protein is heterologous to said microorganism.

16. The method of Claim 13 wherein said gram-positive microorganism is a Bacillus.

17. The method of Claim 16 wherein said Bacillus includes B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. coagulans, B. circulans, B. lautus and Bacillus thuringiensis.

18. The method of Claim 13 wherein said protein includes hormones, enzymes, growth factor and cytokine.

19. The method of Claim 18 wherein said protein is an enzyme.

20. The method of Claim 19 wherein said enzyme includes protease, lipase, amylase, pullulanase, cellulase, glucose isomerase, laccase and a protein disulfide isomerase.

21. A method for producing a product in a gram-positive microorganism comprising the steps of: WO 99/27107 PCTIUS98/24873 -- 28 - a) obtaining a gram-positive microorganism capable of expressing said product said microorganism having a mutation in the nucleic acid encoding either one or both of FTAP I and FTAP 2 said mutation resulting in inhibition of production by said microorganism of the FTAP 1 and/or FTAP 2 activity; and b) culturing said microorganism under conditions suitable for expression of said product.

22. A method for producing a product in a gram-positive microorganism comprising the steps of a) obtaining a gram-positive microorganism capable of expressing said product; b) modifying the expression of FMD in said microorganism; and c) culturing said microorganism under conditions suitable for expression of said product.

23. The method of Claim 21 or 22 wherein said product is a recombinant protein.

24. A method for modifying the growth of gram-positive microorganisms comprising modifying formate transport in the gram-positive microorganism.

25. A gram-positive microorganism comprising an isolated nucleic acid encoding either one or both of FTAP 1 and FTAP 2.

26. A gram positive microorganism having a mutation of the gene encoding PurU said mutation resulting in the inhibition of PurU activity.

27. The microorganism of Claim 25 or 26 further comprising nucleic acid encoding a protein.

28. The microorganism of Claim 27 wherein said protein is an enzyme.

29. The microorganism of Claim 28 wherein said enzyme includes protease, lipase, amylase, pullulanase, cellulase, glucose isomerase, laccase and a protein disulfide isomerase.

30. An expression vector comprising nucleic acid encoding at least one of FTAP 1, FTAP 2, PurU and FMD.

31. A host cell comprising the expression vector of Claim 30.